Glatiramer acetate and interferon beta 1a and 1b for clinically isolated syndrome a review of clinical effectiveness and guidelines
This review aims to summarize and evaluate evidence regarding the clinical effectiveness and safety of glatiramer acetate, IFN beta-1a, and IFN beta-1b, in treating patients with clinically isolated syndrome (CIS). The review also aims to summarize and assess relevant evidence-based guidelines
| Main Authors: | , |
|---|---|
| Corporate Author: | |
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
September 18, 2019, 2019
|
| Edition: | Version: 1.0 |
| Series: | CADTH rapid response report: summary with critical appraisal
|
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | This review aims to summarize and evaluate evidence regarding the clinical effectiveness and safety of glatiramer acetate, IFN beta-1a, and IFN beta-1b, in treating patients with clinically isolated syndrome (CIS). The review also aims to summarize and assess relevant evidence-based guidelines |
|---|---|
| Physical Description: | 1 PDF file (32 pages) illustrations |